Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emerald Health Therapeutics Inc TBQBF


Primary Symbol: EMHTF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and production excellence.


OTCQB:EMHTF - Post by User

Emerald Health Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by gdown9on Aug 27, 2018 8:50am
65 Views
Post# 28520940

News this morning aligns with Midas Letter nicely

News this morning aligns with Midas Letter nicely
In fact, IMHO, this aligns very nicely with what was discussed in the most recent Midas Letter @ https://midasletter.com/2018/08/video-emerald-health-therapeutics-cveemh-development-push/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities